MGC Pharmaceuticals Ltd (ASX:MXC)

Click MGC Pharmaceuticals Ltd (ASX:MXC) share price

MGC Pharmaceuticals Ltd (ASX: MXC) is a European based bio-pharma company developing and supplying affordable standardised phytocannabinoid derived medicines to patients globally. 

The Company’s founders were key figures in the global medical cannabis industry and the core business strategy is to develop and supply high quality phytocannabinoid derived medicines for the growing demand in the medical markets in Europe, North America and Australasia. MGC Pharma has a robust product offering targeting two widespread medical conditions – epilepsy and dementia – and has further products in the development pipeline.

Employing its ‘Nature to Medicine’ strategy, MGC Pharma has partnered with renowned institutions and academia to optimise cultivation and the development of targeted phytocannabinoid derived medicines products prior to production in the Company’s EU-GMP Certified manufacturing facility. 

MGC Pharma has a number of research collaborations with world renowned academic institutions, and including recent research highlighting the positive impact of using specific phytocannabinoid formulations developed by MGC Pharma in the treatment of glioblastoma, the most aggressive and so far therapeutically resistant primary brain tumour.

MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.

MGC Pharmaceuticals acquires 40% equity stake in UK-based ZAM Software

MGC Pharmaceuticals gives update on its drug for COVID-19 and post COVID-19 syndrome

Phytocannabinoid medicine company, MGC Pharmaceuticals to list on LSE

MGC Pharmaceuticals completes acquisition of Australian Medicinal Cannabis Clinics

MGC Pharma submits patent application for CimetrA to European IP Office

MGC Pharma to acquire Israel based MediCaNL for $6.0 million in shares

MGC signs distribution agreement signed with UK medicinal cannabis provider LYPHE

MGC Pharma signed binding term sheet to acquire Medicinal Cannabis Clinic

MGC Pharma receives cannabis cultivation research permit from Australian ODC

MGC Pharma signs commercial supply deal for first products into Poland

MGC Pharma signs agreement for entry of cannabinoid medicines into new markets

MGC launches new Cannabinoid products line in Australia & New Zealand

CimetrA import approval granted in India

THC Global to supply Canndeo products into Australia & New Zealand markets

Leave a Reply

Your email address will not be published. Required fields are marked *